STOCK TITAN

Fulgent Genetics, Inc. (FLGT) president reports 4,361-share tax withholding

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Fulgent Genetics, Inc. President and COO Jian Xie reported a tax‑withholding disposition of 4,361 shares of common stock on July 26, 2026, at $19.67 per share, to cover taxes from vesting restricted stock units. After this, he directly held 363,244 shares, with an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Xie Jian
Role President and COO
Type Security Shares Price Value
Tax Withholding Common Stock F1 4,361 $19.67 $86K
holding Common Stock F2 -- -- --
Holdings After Transaction: Common Stock — 363,244 shares (Direct); Common Stock — 220,816 shares (Indirect, By Trust)
Footnotes (2)
  1. F1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.
  2. F2. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
Shares withheld for taxes 4,361 shares Common stock withheld on July 26, 2026 to satisfy tax withholding obligations from RSU vesting
Withholding price per share $19.67 per share Value used for the 4,361-share tax-withholding disposition on July 26, 2026
Direct holdings after transaction 363,244 shares Jian Xie’s directly owned Fulgent Genetics common shares following the tax-withholding transaction
Indirect trust holdings 220,816 shares Shares held by The Hsieh Family Dynasty Trust, where Jian Xie serves on the investment committee
restricted stock units financial
"upon the vesting of certain restricted stock units assumed"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"to satisfy the tax withholding obligations that arose"
pecuniary interest financial
"disclaims any beneficial interest except with respect to any pecuniary interest"
investment committee financial
"Mr. Xie serves on the investment committee of the Trust"
An investment committee is a small group of experienced people who set the rules and make the key decisions about what investments to buy, hold, or sell for a fund, pension, or portfolio. Think of them as the steering team that balances goals, potential returns and risk—their choices shape how much money investors are likely to gain or lose and provide consistent oversight so decisions aren’t made impulsively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Fulgent Genetics (FLGT) report for Jian Xie?

Fulgent Genetics reported that President and COO Jian Xie had 4,361 shares of common stock withheld on July 26, 2026 at $19.67 per share. The shares were used to satisfy tax withholding obligations from vesting restricted stock units assumed in a prior merger.

Was Jian Xie’s FLGT Form 4 transaction an open-market sale?

No, Jian Xie’s reported transaction was a tax-withholding disposition, not an open-market sale. 4,361 shares were withheld by the issuer to cover taxes due upon RSU vesting, as described in the footnote, rather than being sold on the market.

How many Fulgent Genetics (FLGT) shares does Jian Xie hold after the transaction?

After the July 26, 2026 transaction, Jian Xie directly held 363,244 shares of Fulgent Genetics common stock. In addition, 220,816 shares are held indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee with only pecuniary beneficial interest.

What is the role of The Hsieh Family Dynasty Trust in Jian Xie’s FLGT holdings?

The Hsieh Family Dynasty Trust holds 220,816 Fulgent Genetics shares as an indirect holding for Jian Xie. He serves on the Trust’s investment committee and disclaims beneficial interest except for any pecuniary interest, according to the Form 4 footnote.

What triggered the tax withholding on Jian Xie’s FLGT shares?

The withholding of 4,361 shares was triggered by the vesting of restricted stock units assumed under a November 7, 2022 merger agreement. The shares were withheld to satisfy tax withholding obligations arising from that RSU vesting event.

Is Jian Xie’s FLGT Form 4 transaction under a Rule 10b5-1 trading plan?

The Form 4 indicates the transaction was not made under a Rule 10b5-1 trading plan. The filing’s 10b5‑1 checkbox is explicitly unchecked, distinguishing this tax-withholding disposition from trades executed pursuant to a pre-arranged trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Xie Jian

(Last)(First)(Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE

(Street)
EL MONTE CALIFORNIA 91731

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President and COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/26/2026F4,361(1)D$19.67363,244D
Common Stock220,816IBy Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.
2. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
/s/ Paul Kim as Attorney-in-Fact07/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)